• Profile

High anti-TNFα concentrations are not associated with more adverse events in pediatric inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition Nov 26, 2021

Zvuloni M, Matar M, Levi R, et al. - Since risks for adverse events are associated with anti-tumor necrosis factor alpha (anti-TNFα) therapy for refractory pediatric inflammatory bowel disease (IBD), this study was run to unveil the association between anti-TNFα trough levels and adverse events rate among pediatric patients suffering from IBD.

  • A total of 135 pediatric patients with IBD (59 [43.7%] girls, mean age at diagnosis 12.9 [±3] years, 111 [82.2%] Crohn disease) who were treated with anti-TNFα agents and had sequential monitoring of trough concentration (TC) (1589 measurements) were analyzed retrospectively.

  • A median follow-up of 1.7 years (IQR 1.1–2.7) revealed the occurrence of 156 adverse events in 50 patients (37%).

  • There was no association of higher TCs with higher rate of anti-TNFα-related adverse events.

  • Whereas, such adverse events (excluding increase in liver transaminases) were related to younger age.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen